Evidence map›Paper›PMID 35390025›Full record

ArticlePloS one2022

How useful are body mass index and history of diabetes in COVID-19 risk stratification?

Sarah-Jeanne Salvy, Geetanjali D Datta, Qihan Yu, Marie Lauzon, Shehnaz K Hussain, Susan Cheng, Joseph E Ebinger, Mark O Goodarzi, Jane C Figueiredo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sarah-Jeanne SalvyCancer Research Center for Health Equity, Cedars-Sinai Medical Center, West Hollywood, CA, United States of America.ORCID 0000-0002-8202-182X
Geetanjali D DattaCancer Research Center for Health Equity, Cedars-Sinai Medical Center, West Hollywood, CA, United States of America.
Qihan YuCancer Research Center for Health Equity, Cedars-Sinai Medical Center, West Hollywood, CA, United States of America.
Marie LauzonSamuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, United States of America.
Shehnaz K HussainDepartment of Public Health Sciences, UC Davis School of Medicine and Comprehensive Cancer Center, Davis, CA, United States of America.
Susan ChengDepartment of Cardiology, Smidt Heart Institute and Barbra Streisand Women's Heart Center Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Joseph E EbingerDepartment of Cardiology and Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Mark O GoodarziDivision of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.ORCID 0000-0001-6364-5103
Jane C FigueiredoCancer Research Center for Health Equity, Cedars-Sinai Medical Center, West Hollywood, CA, United States of America.ORCID 0000-0001-8040-3341
Cedars-Sinai Medical Center · USSamueli Institute · USUniversity of California, Davis · US

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
Evaluating environmental control (AVOID) and inhibitory control (RESIST) strategies to improve weight management outcomesR01DK130851 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Sarah-Jeanne Salvy · 2022 to 2026
$3.5M
NIDDK NIH HHS P30 DK063491NIDDK NIH HHS R01 DK130851
6 · The paper itself

Abstract

objectiveThis study examines the value of risk stratification by documented diagnosis of diabetes and objectively measured height and weight (BMI) in COVID-19 severity and mortality in a large sample of patients in an urban hospital located in Southern California.

methodsData from a retrospective cohort study of COVID-19 patients treated at Cedars-Sinai Medical Center between March 8, 2020, and January 25, 2021, was analyzed. Sociodemographic characteristics and pre-existing conditions were extracted from electronic medical records. Univariable and multivariable logistic regression models identified associated risk factors, and a regression causal mediation analysis examined the role of diabetes in the association between obesity and illness severity. All analyses were stratified by age (<65 and ≥65).

resultsAmong individuals <65yo, diabetes accounted for 19-30% of the associations between obesity and COVID-19 illness severity. Among patients ≥65yo, having a BMI <18.5 was a risk factor for mortality regardless of diabetes history.

conclusionOur findings have clinical implications in documenting which patients may be at elevated risk for adverse outcomes. More in-depth prospective studies are needed to capture how glycemic regulation may influence prognosis.

Indexed as

COVID-19Diabetes MellitusBody Mass IndexHumansObesityRetrospective StudiesRisk AssessmentRisk FactorsSARS-CoV-2

Identifiers

PMID35390025
PMCPMC8989225
OpenAlexW4226515164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.